Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Medmira (47M) Stock Price & Analysis

47M Stock Chart & Stats

€0.02€0.00(0.00%)
At close: 5:30 PM GMT+1
EUR 0.025EUR 0.05EUR 0.075EUR 0.130 Mar3 Aug1 Feb8 Oct3 Apr9 Sep16 Feb5 Oct
Day’s Range
EUR 0.02 - EUR 0.03
52-Week Range
EUR 0.02 - EUR 0.05
Previous Close
EUR 0.02
Volume
0
Average Volume (3M)
191
Market Cap
EUR 23.75M
Enterprise Value
EUR 55.31T
Total Cash (Recent Filing)
EUR 0
Total Debt (Recent Filing)
EUR 17.42M
Price to Earnings (P/E)
―
Beta
0.01
Next Earnings
Dec 02, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Rebound

The TTM revenue rebound indicates materially stronger product demand and market activity. If sustained, higher sales can improve operating leverage and support scale across healthcare and public-health customers, although profitability conversion remains unproven.

Reusable RVF Technology Platform

An RVF platform supporting HIV and HCV assays gives MedMira a reusable technology base rather than a single-product proposition. Broader infectious-disease applications can support product extensions, channel reach and future customer retention.

Recurring Consumables Model

Diagnostic kits are bought by clinics, hospitals, laboratories, public-health agencies and distributors. Continued testing creates a structural opportunity for repeat orders, while direct and distribution channels can widen access without relying on one customer route.

Bears Say

Persistent Unprofitability

Deeply negative gross margin and continuing operating and net losses show that revenue growth has not yet translated into viable unit economics. Without sustained gross-profit improvement, future scale could increase losses rather than create durable earnings.

Negative Cash Generation

Negative operating cash flow and free cash flow in every period indicate the business cannot currently fund itself. Ongoing burn raises dependence on external financing and constrains investment in product development, manufacturing and commercialization.

Stressed Balance Sheet

Negative shareholders’ equity, substantial debt and limited assets leave little balance-sheet cushion. This leverage profile increases solvency risk and may weaken negotiating power with lenders, suppliers and strategic partners.

Medmira News

47M FAQ

What was Medmira’s price range in the past 12 months?
Medmira lowest stock price was €0.02 and its highest was €0.05 in the past 12 months.
What is Medmira’s market cap?
Medmira’s market cap is €23.75M.
When is Medmira’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Medmira’s earnings last quarter?
Medmira released its earnings results on Jun 30, 2026. The company reported -€0.001 earnings per share for the quarter.
Is Medmira overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Medmira pay dividends?
Medmira does not currently pay dividends.
What is Medmira’s EPS estimate?
Medmira’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medmira have?
Medmira has 701,730,600 shares outstanding.
What happened to Medmira’s price movement after its last earnings report?
Medmira reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Medmira?
Currently, no hedge funds are holding shares in DE:47M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology